Suven Life Science is exhibiting and presenting several exciting new results and data presentations from Suven’s portfolio of investigational Neuroscience New Chemical Entities (NCEs) which has being presented at Alzheimer's Association International Conference (AAIC) being held in Chicago, USA starting July 22 to 26, 2018.
Alzheimer’s disease is one of the scourges of modern day health care. Alzheimer’s is not just a memory loss as everyone thinks but Alzheimer’s kills. Current Alzheimer's treatments cannot stop Alzheimer's from progressing, they can temporarily slow the worsening of dementia symptoms and improve quality of life.
There is a worldwide effort under way to find better ways to treat the disease, delay its onset and prevent it from developing and this is where Suven is focusing on developing drugs for the treatment of this debilitating disease. Suven has excellent portfolio of new molecules through 4 mechanisms of action using 5-HT6, 5-HT4, H3 receptors and M1PAM for the symptomatic treatment of cognitive impairment in Alzheimer’s disease but also possibly useful in reducing the disease progression.
